195 related articles for article (PubMed ID: 29111717)
1. Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate.
Crosignani S; Bingham P; Bottemanne P; Cannelle H; Cauwenberghs S; Cordonnier M; Dalvie D; Deroose F; Feng JL; Gomes B; Greasley S; Kaiser SE; Kraus M; Négrerie M; Maegley K; Miller N; Murray BW; Schneider M; Soloweij J; Stewart AE; Tumang J; Torti VR; Van Den Eynde B; Wythes M
J Med Chem; 2017 Dec; 60(23):9617-9629. PubMed ID: 29111717
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.
Gomes B; Driessens G; Bartlett D; Cai D; Cauwenberghs S; Crosignani S; Dalvie D; Denies S; Dillon CP; Fantin VR; Guo J; Letellier MC; Li W; Maegley K; Marillier R; Miller N; Pirson R; Rabolli V; Ray C; Streiner N; Torti VR; Tsaparikos K; Van den Eynde BJ; Wythes M; Yao LC; Zheng X; Tumang J; Kraus M
Mol Cancer Ther; 2018 Dec; 17(12):2530-2542. PubMed ID: 30232146
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Clinical Candidate (1
Kumar S; Waldo JP; Jaipuri FA; Marcinowicz A; Van Allen C; Adams J; Kesharwani T; Zhang X; Metz R; Oh AJ; Harris SF; Mautino MR
J Med Chem; 2019 Jul; 62(14):6705-6733. PubMed ID: 31264862
[TBL] [Abstract][Full Text] [Related]
4. Indol-2-yl ethanones as novel indoleamine 2,3-dioxygenase (IDO) inhibitors.
Dolušić E; Larrieu P; Blanc S; Sapunaric F; Norberg B; Moineaux L; Colette D; Stroobant V; Pilotte L; Colau D; Ferain T; Fraser G; Galleni M; Frère JM; Masereel B; Van den Eynde B; Wouters J; Frédérick R
Bioorg Med Chem; 2011 Feb; 19(4):1550-61. PubMed ID: 21269836
[TBL] [Abstract][Full Text] [Related]
5. Discovery and preliminary SARs of keto-indoles as novel indoleamine 2,3-dioxygenase (IDO) inhibitors.
Dolušić E; Larrieu P; Blanc S; Sapunaric F; Pouyez J; Moineaux L; Colette D; Stroobant V; Pilotte L; Colau D; Ferain T; Fraser G; Galleni M; Frère JM; Masereel B; Van den Eynde B; Wouters J; Frédérick R
Eur J Med Chem; 2011 Jul; 46(7):3058-65. PubMed ID: 21419531
[TBL] [Abstract][Full Text] [Related]
6. Identification and optimization of a novel series of indoleamine 2,3-dioxygenase inhibitors.
Markwalder JA; Seitz SP; Blat Y; Elkin L; Hunt JT; Pabalan JG; Jure-Kunkel MN; Vite GD; Covello K
Bioorg Med Chem Lett; 2017 Feb; 27(3):582-585. PubMed ID: 28003141
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationship and enzyme kinetic studies on 4-aryl-1H-1,2,3-triazoles as indoleamine 2,3-dioxygenase (IDO) inhibitors.
Huang Q; Zheng M; Yang S; Kuang C; Yu C; Yang Q
Eur J Med Chem; 2011 Nov; 46(11):5680-7. PubMed ID: 21925773
[TBL] [Abstract][Full Text] [Related]
8. Molecular docking and dynamic simulation studies evidenced plausible immunotherapeutic anticancer property by Withaferin A targeting indoleamine 2,3-dioxygenase.
Reddy SV; Reddy KT; Kumari VV; Basha SH
J Biomol Struct Dyn; 2015; 33(12):2695-709. PubMed ID: 25671592
[TBL] [Abstract][Full Text] [Related]
9. Biochemical properties of indoleamine 2,3-dioxygenase: from structure to optimized design of inhibitors.
Lancellotti S; Novarese L; De Cristofaro R
Curr Med Chem; 2011; 18(15):2205-14. PubMed ID: 21517759
[TBL] [Abstract][Full Text] [Related]
10. The selenazal drug ebselen potently inhibits indoleamine 2,3-dioxygenase by targeting enzyme cysteine residues.
Terentis AC; Freewan M; Sempértegui Plaza TS; Raftery MJ; Stocker R; Thomas SR
Biochemistry; 2010 Jan; 49(3):591-600. PubMed ID: 20000778
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors.
Gaspari P; Banerjee T; Malachowski WP; Muller AJ; Prendergast GC; DuHadaway J; Bennett S; Donovan AM
J Med Chem; 2006 Jan; 49(2):684-92. PubMed ID: 16420054
[TBL] [Abstract][Full Text] [Related]
12. Computational study on new natural compound inhibitors of indoleamine 2,3-dioxygenase 1.
Jiang S; Li H; Piao L; Jin Z; Liu J; Chen S; Liu LL; Shao Y; Zhong S; Wu B; Li W; Ren J; Zhang Y; Wang H; Jin R
Aging (Albany NY); 2020 Jun; 12(12):11349-11363. PubMed ID: 32568737
[TBL] [Abstract][Full Text] [Related]
13. Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
Hanihara M; Kawataki T; Oh-Oka K; Mitsuka K; Nakao A; Kinouchi H
J Neurosurg; 2016 Jun; 124(6):1594-601. PubMed ID: 26636389
[TBL] [Abstract][Full Text] [Related]
14. Discovery and structure-activity relationships of phenyl benzenesulfonylhydrazides as novel indoleamine 2,3-dioxygenase inhibitors.
Cheng MF; Hung MS; Song JS; Lin SY; Liao FY; Wu MH; Hsiao W; Hsieh CL; Wu JS; Chao YS; Shih C; Wu SY; Ueng SH
Bioorg Med Chem Lett; 2014 Aug; 24(15):3403-6. PubMed ID: 24939758
[TBL] [Abstract][Full Text] [Related]
15. Discovery of 5-(pyridin-3-yl)-1H-indole-4,7-diones as indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
Kong KM; Zhang JW; Liu BZ; Meng GR; Zhang Q
Bioorg Med Chem Lett; 2020 Feb; 30(4):126901. PubMed ID: 31882299
[TBL] [Abstract][Full Text] [Related]
16. Targeting indoleamine 2,3-dioxygenase (IDO) to counteract tumour-induced immune dysfunction: from biochemistry to clinical development.
Rutella S; Bonanno G; De Cristofaro R
Endocr Metab Immune Disord Drug Targets; 2009 Jun; 9(2):151-77. PubMed ID: 19519465
[TBL] [Abstract][Full Text] [Related]
17. Exiguamine A, an indoleamine-2,3-dioxygenase (IDO) inhibitor isolated from the marine sponge Neopetrosia exigua.
Brastianos HC; Vottero E; Patrick BO; Van Soest R; Matainaho T; Mauk AG; Andersen RJ
J Am Chem Soc; 2006 Dec; 128(50):16046-7. PubMed ID: 17165752
[TBL] [Abstract][Full Text] [Related]
18. Research progress of indoleamine 2,3-dioxygenase inhibitors.
Jiang T; Sun Y; Yin Z; Feng S; Sun L; Li Z
Future Med Chem; 2015; 7(2):185-201. PubMed ID: 25686005
[TBL] [Abstract][Full Text] [Related]
19. 4-Bromophenylhydrazinyl benzenesulfonylphenylureas as indoleamine 2,3-dioxygenase inhibitors with in vivo target inhibition and anti-tumor efficacy.
Lin SY; Yeh TK; Song JS; Hung MS; Cheng MF; Liao FY; Li AS; Cheng SY; Lin LM; Chiu CH; Wu MH; Lin YJ; Hsiao W; Sun M; Wang YH; Huang CH; Tang YC; Chang HH; Huang ZT; Chao YS; Shih C; Pan SL; Wu SY; Kuo CC; Ueng SH
Bioorg Chem; 2018 Apr; 77():600-607. PubMed ID: 29494816
[TBL] [Abstract][Full Text] [Related]
20. Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease.
Macchiarulo A; Camaioni E; Nuti R; Pellicciari R
Amino Acids; 2009 Jul; 37(2):219-29. PubMed ID: 18612775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
